(S)-4-(5,7-dibromo-2,3-dihydro-1H-indol-1-yl)-1-[1-(methoxymethyl)-3-methoxypropyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-4-(5,7-dibromo-2,3-dihydro-1H-indol-1-yl)-1-[1-(methoxymethyl)-3-methoxypropyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridine
• 英文别名: 4-(5,7-dibromo-2,3-dihydroindol-1-yl)-1-[(2S)-1,4-dimethoxybutan-2-yl]-6-methyltriazolo[4,5-c]pyridine
• 化学式: C₂₀H₂₃Br₂N₅O₂
• 分子量: 525.243
• InChiKey: FZTBYFWAJGWHEA-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  65.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5,7-dibromoindoline 、 (S)-4-chloro-1-(1-methoxymethyl-3-methoxypropyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridine 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 以85%的产率得到(S)-4-(5,7-dibromo-2,3-dihydro-1H-indol-1-yl)-1-[1-(methoxymethyl)-3-methoxypropyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridine
  参考文献：
  名称：

  Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders

  摘要：

  皮质释放因子（CRF）拮抗剂的化学式（I）：及其在治疗精神障碍和神经系统疾病、焦虑相关障碍、创伤后应激障碍、上核性麻痹和进食障碍以及治疗与哺乳动物中的心理病理紊乱和应激相关的结肠过敏性所关联的免疫、心血管或心脏疾病方面的用途。

  公开号：

  US06245769B1

文献信息

• Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
  申请人：——

  公开号：US20010025042A1

  公开（公告）日：2001-09-27

  Corticotropin releasing factor (CRF) antagonists of Formula (I): 1 and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

  Corticotropin releasing factor (CRF)拮抗剂的公式（I）：1及其用于治疗精神障碍和神经系统疾病、焦虑相关障碍、创伤后应激障碍、上行性麻痹和进食障碍，以及治疗哺乳动物中与心理病理紊乱和压力相关的免疫、心血管或心脏相关疾病和结肠过敏性反应。
• HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1012151B1

  公开（公告）日：2002-08-07
• US6245769B1
  申请人：——

  公开号：US6245769B1

  公开（公告）日：2001-06-12
• US6525056B2
  申请人：——

  公开号：US6525056B2

  公开（公告）日：2003-02-25
• Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
  申请人：DuPont Pharmaceuticals Company

  公开号：US06245769B1

  公开（公告）日：2001-06-12

  Corticotropin releasing factor (CRF) antagonists of Formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

  皮质释放因子（CRF）拮抗剂的化学式（I）：及其在治疗精神障碍和神经系统疾病、焦虑相关障碍、创伤后应激障碍、上核性麻痹和进食障碍以及治疗与哺乳动物中的心理病理紊乱和应激相关的结肠过敏性所关联的免疫、心血管或心脏疾病方面的用途。